Radiation

Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates

Thursday, August 5, 2021 - 9:01pm

WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates.

Key Points: 
  • WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates.
  • The Company currently has 12 participating trial sites, with data anticipated in the fourth quarter of 2021.
  • Research and development expenses were $4.2 million for the second quarter of 2021, compared to $4.5 million for the second quarter of 2020.
  • General and administrative expenses for the second quarter of 2021 were $3.4 million, compared to $3.5 million for the second quarter of 2020.

Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian

Thursday, August 5, 2021 - 4:00pm

Australia's Icon Group will become the first in the world to deploy this new system, which is scheduled for release in Australia and other global sites in early 2022.

Key Points: 
  • Australia's Icon Group will become the first in the world to deploy this new system, which is scheduled for release in Australia and other global sites in early 2022.
  • After a successful deployment, the new ARIA system will serve as Icon's next-generation platform for enhancing clinical operations, and further deployments at other Icon sites will commence.
  • Mark Middleton, CEO, Icon Group, said, "Icon is delighted to once again be at the forefront of technology evolution alongside Varian.
  • ARIA is Varian's comprehensive oncology information system for managing clinical, administrative, and financial processes in comprehensive cancer treatment environments.

TeamViewer and Siemens Healthineers Form Partnership to Enable New Remote Scanning Service WeScan for Diagnostic Imaging

Thursday, August 5, 2021 - 2:00pm

TAMPA BAY, Fla., Aug. 5, 2021 /PRNewswire/ -- Siemens Healthineers has recently started offering its customers WeScan1. WeScan is a new service leveraging TeamViewer's connectivity technology, that helps healthcare providers to perform magnetic resonance imaging (MRI) examinations if they lack qualified radiology staff. With the WeScan service, customers may seek access to a pool of skilled remote imaging technologists who help operate the MRI scanner using syngo Virtual Cockpit, the remote scanning software of Siemens Healthineers. As Siemens Healthineers assists customers via WeScan from outside their own IT-network, real-time data transmission across the internet and high security standards are central requirements. Therefore, Siemens Healthineers has formed a new partnership with TeamViewer. TeamViewer's remote connectivity technology is now incorporated as part of the WeScan service offering because of its high security standards, powerful data transfer performance, and ease of operation.

Key Points: 
  • With the WeScan service, customers may seek access to a pool of skilled remote imaging technologists who help operate the MRI scanner using syngo Virtual Cockpit, the remote scanning software of Siemens Healthineers.
  • As Siemens Healthineers assists customers via WeScan from outside their own IT-network, real-time data transmission across the internet and high security standards are central requirements.
  • "TeamViewer has been an important partner for many years," says Wolfgang Heimsch, Head of Customer Services at Siemens Healthineers.
  • Lukas Baur, EVP Solution Sales at TeamViewer, comments: "With WeScan, Siemens Healthineers is offering a highly innovative service that provides genuine added value for its customers.

Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Thursday, August 5, 2021 - 12:30pm

AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a Company overview during the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12th at 4:30 p.m.

Key Points: 
  • AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a Company overview during the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12th at 4:30 p.m.
  • Investors interested in arranging a meeting with the Companys management should contact the Canaccord Genuity conference coordinator.
  • Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.
  • Central to the Companys drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases.

Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)

Thursday, August 5, 2021 - 12:00pm

As of August 4, 2021, total trial enrollment for the Phase 1b/2 trial including primary and exploratory cohorts was 51 patients.

Key Points: 
  • As of August 4, 2021, total trial enrollment for the Phase 1b/2 trial including primary and exploratory cohorts was 51 patients.
  • Cavrotolimod is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.
  • In December 2019, Exicure announced preliminary results from the Phase 1b stage of the clinical trial including potential signs of anti-tumor activity with cavrotolimod in combination with pembrolizumab in cancer patients.
  • Exicure's therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Wednesday, August 4, 2021 - 11:30pm

MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces today that the first patient has been dosed in its CUPID first-in-human Phase I study of the Companys next generation prostate cancer therapy candidate TLX592 in patients with advanced prostate cancer.

Key Points: 
  • MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces today that the first patient has been dosed in its CUPID first-in-human Phase I study of the Companys next generation prostate cancer therapy candidate TLX592 in patients with advanced prostate cancer.
  • This investigational agent will become Telixs first targeted alpha therapy (TAT) for the treatment of patients with advanced prostate cancer.
  • TLX592 targets prostate specific membrane antigen (PSMA)1, as does the Companys existing TLX591 (177Lu-rosapatamab) prostate cancer therapy program.
  • The very high energy, short range properties of targeted alpha therapy have the potential to offer a potent and highly selective anti-cancer therapy to patients with advanced prostate cancer.

OrthoPediatrics Corp. and Mighty Oak Medical Extend Exclusive Partnership for FIREFLY Technology in Pediatric Orthopedics

Wednesday, August 4, 2021 - 12:00pm

Since August 2017, OrthoPediatrics has been the exclusive distributor of Mighty Oak Medicals FIREFLY Technology in childrens hospitals across the United States.

Key Points: 
  • Since August 2017, OrthoPediatrics has been the exclusive distributor of Mighty Oak Medicals FIREFLY Technology in childrens hospitals across the United States.
  • Manufactured by Might Oak Medical, FIREFLY Pedicle Screw Navigation Guides are 3D printed and patient-specific at each planned vertebral level.
  • OrthoPediatrics regards this partnership as a great synergy and has enjoyed working with Mighty Oak Medical to make scoliosis easier for surgeons, and surgery safer for KIDS.
  • OrthoPediatrics Chief Financial Officer, and Chief Operating Officer Fred Hite, said, We are delighted to continue our partnership with Mighty Oak Medical.

Electromagnetic Interference (EMI) Shielding Market Size To Reach USD 9.69 Billion in 2028 | Reports and Data

Wednesday, August 4, 2021 - 3:00pm

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- According to the latest report offered by Reports and Data, the GlobalElectromagnetic Interference (EMI) Shielding Market size is expected to exceed USD 9.69 Billion and register a revenue CAGR of 5.0% over the forecast period.

Key Points: 
  • NEW YORK, Aug. 4, 2021 /PRNewswire/ -- According to the latest report offered by Reports and Data, the GlobalElectromagnetic Interference (EMI) Shielding Market size is expected to exceed USD 9.69 Billion and register a revenue CAGR of 5.0% over the forecast period.
  • Tapes and laminates are widely used in applications requiring a reliable electrical contact, specifically for grounding, electromagnetic shielding, and charge draining.
  • Robust revenue growth can be attributed to extensive deployment of EMI metal shielding for electronic/electrical device protection from radiation and interference.
  • China, being a major manufacturing hub for various electronic devices, accounts for substantially high demand for EMI shielding.

Electromagnetic Interference (EMI) Shielding Market Size To Reach USD 9.69 Billion in 2028 | Reports and Data

Wednesday, August 4, 2021 - 3:00pm

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- According to the latest report offered by Reports and Data, the Global Electromagnetic Interference (EMI) Shielding Market size is expected to exceed USD 9.69 Billion and register a revenue CAGR of 5.0% over the forecast period. Key factors such as increasing demand for a variety of advanced and smart consumer electronics goods and appliances, ongoing pilot projects and field trials to check viability of 5G technology, and increasing electromagnetic pollution are driving robust global EMI shielding market revenue growth currently.

Key Points: 
  • Market Size USD 6.72 Billion in 2020, Market Growth - CAGR of 5.0%, Market Trends Compliance with stringent EMC Requirements
    NEW YORK, Aug. 4, 2021 /PRNewswire/ -- According to the latest report offered by Reports and Data, the GlobalElectromagnetic Interference (EMI) Shielding Market size is expected to exceed USD 9.69 Billion and register a revenue CAGR of 5.0% over the forecast period.
  • Tapes and laminates are widely used in applications requiring a reliable electrical contact, specifically for grounding, electromagnetic shielding, and charge draining.
  • Robust revenue growth can be attributed to extensive deployment of EMI metal shielding for electronic/electrical device protection from radiation and interference.
  • Some major companies operating in the global EMI shielding market include:

Olympia's UVT (UVC Troffer) Wins EC&M Product of the Year for 2021

Tuesday, August 3, 2021 - 1:38pm

The company managed to secure the top spot in their Product of the Year competition.

Key Points: 
  • The company managed to secure the top spot in their Product of the Year competition.
  • In particular, the UVC Troffer, which was the winner of the EC&M award category for lamps.
  • It should come as no surprise that the LED Troffer light fixtures and LED Troffer lights ended up at the top of the list.
  • Creating cutting-edge solutions, Olympia's products are competitively priced and come with up to 100,000 hours, 10-year manufacturer warranty.